TY  - JOUR
PY  - 2016//
TI  - Notes from the field: Pediatric emergency department visits for buprenorphine/naloxone ingestion - United States, 2008-2015
JO  - MMWR: Morbidity and mortality weekly report
A1  - Budnitz, Daniel S.
A1  - Lovegrove, Maribeth C.
A1  - Sapiano, Mathew R. P.
A1  - Mathew, Justin
A1  - Kegler, Scott R.
A1  - Geller, Andrew I.
A1  - Hampp, Christian
SP  - 1148
EP  - 1149
VL  - 65
IS  - 41
N2  - Expanding access to office-based medication-assisted treatment with buprenorphine/naloxone for opioid dependence is a key part of the national strategy to address the opioid abuse epidemic (1). However, as buprenorphine/naloxone prescribing increased, emergency department (ED) visits and hospitalizations for unsupervised ingestions by young children began to increase, with buprenorphine/naloxone ingestions becoming the most common cause of hospitalization for medication ingestions by young children during 2010-2011 (2). Buprenorphine ingestions might be asymptomatic or can cause drowsiness, vomiting, or respiratory depression, which if untreated can result in death (3). Buprenorphine/naloxone was available only as tablets in multidose child-resistant bottles (Suboxone) until late 2010, when film strips packaged in unit-dose, child-resistant pouches were introduced. In 2013, tablets became available in unit-dose packaging (Zubsolv). Because unit-dose, child-resistant packaging encloses each dose until opened, it might limit unintended ingestions by young children compared with traditional child-resistant bottles that must be resecured after every use (4). This study compared ED visits for pediatric buprenorphine/naloxone ingestions before and after these product packaging/formulation changes.<p />  <p>Language: en</p>
LA  - en
SN  - 0149-2195
UR  - http://dx.doi.org/10.15585/mmwr.mm6541a5
ID  - ref1
ER  -